Therapeutic Lymphangiogenesis Using Induced Cardiac Fibroblasts Protects the Heart From Heart Failure With Preserved Ejection Fraction Progression by Exerting Anti-Inflammatory and Antifibrotic Effects | Synapse
March 3, 2026Open Access
Therapeutic Lymphangiogenesis Using Induced Cardiac Fibroblasts Protects the Heart From Heart Failure With Preserved Ejection Fraction Progression by Exerting Anti-Inflammatory and Antifibrotic Effects
Key Points
Heart failure with preserved ejection fraction can be mitigated through therapeutic lymphangiogenesis, potentially halting disease progression.
The study highlights the role of cardiac fibroblasts in exerting anti-inflammatory and antifibrotic effects during this process.
Assessment involved understanding the remodeling and function of cardiac lymphatic vessels in heart failure progression.
These findings may indicate a promising therapeutic avenue for heart failure treatment, but further studies are warranted.
Abstract
Cardiac lymphatic vessels play an important role in remodeling and function in HFpEF progression. Moreover, lymphangiogenesis could be a novel therapeutic target for HFpEF.